Livmoniplimab Clinical Trials

2 actively recruiting trials across 2 locations

▼ -1 trial since August 2026

Also known as: ABBV-151

Pipeline

Phase 2/3: 2

Top Sponsors

AbbVie2

Indications

Cancer2
Liver Disease1
Liver Cancer1
Hepatocellular Carcinoma1
Lung Cancer1

Duarte, California1 trial

A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)

City of Hope /ID# 261468

Phase 2/3

La Jolla, California1 trial

Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

UC San Diego Health - Moores Cancer Center /ID# 267782

Phase 2/3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.